Page 4 - Merck Press News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Merck press. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Merck Press Today - Breaking & Trending Today

Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma

Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO® (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma
q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , United States , City Of , Thomas Powles , American Society Of Clinical Oncology , Head Of Development Unit Oncology , Merck Press , European Commission , Drug Administration , Queen Mary University Of London , Solid Tumor Research At Barts Cancer Institute , American Cancer Society , Barts Cancer Centre , United Kingdom Based , Clinical Oncology , Genitourinary Cancers Symposium , Genitourinary Oncology , Solid Tumor Research , Barts Cancer Institute , Queen Mary University , Victoria Zazulina , Development Unit Oncology , Product Characteristics , Merck Press Releases , Cancer Journal , Accessed February ,

Merck: Long-Term Follow-Up Data Reinforce Continued Overall Survival Benefit of BAVENCIO (avelumab) First-Line Maintenance Treatment in Patients with Advanced Urothelial Carcinoma

38-month median follow-up data from the Phase III JAVELIN Bladder 100 trial demonstrated prolonged median OS of 23.8 months with BAVENCIO plus best supportive care (BSC) in the first-line maintenance ....

United States , United Kingdom , City Of , Noelle Piscitelli , Thomas Powles , American Society Of Clinical Oncology , Head Of Development Unit Oncology , Merck Press , European Commission , Drug Administration , Queen Mary University Of London , Solid Tumor Research At Barts Cancer Institute , American Cancer Society , Barts Cancer Centre , United Kingdom Based , Clinical Oncology , Genitourinary Cancers Symposium , Genitourinary Oncology , Solid Tumor Research , Barts Cancer Institute , Queen Mary University , Victoria Zazulina , Development Unit Oncology , Urothelial Carcinoma , Product Characteristics , Merck Press Releases ,

Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics
q8dailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from q8dailynews.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Merck Press , Head Of Global Development , Chord Therapeutics , Danny Bar Zohar , Global Development , Omega Funds , Immunology Merck , All Merck Press Releases ,

Merck Expands Neuroinflammatory Pipeline with Acquisition of Chord Therapeutics

Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). ....

United States , United Kingdom , Brauti Fritzen , Merck Press , Head Of Global Development , Myasthenia Gravis , Neuromyelitis Optica Spectrum Disorder , Multiple Sclerosis , Chord Therapeutics , Danny Bar Zohar , Global Development , Omega Funds , Merck Press Releases , Media Contact , Science And Technology , Chord Therapeutics , Generalized Myasthenia Gravis , Neuromyelitis Optica Spectrum Disorder , Danny Bar Zohar , Omega Funds , Multiple Sclerosis ,

TEPMETKO® (tepotinib) Receives Positive CHMP Opinion for Patients with Advanced NSCLC with METex14 Skipping Alterations

Merck, a leading science and technology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of once-daily oral TEPMETKO® ....

United States , Merck Press , European Commission , Drug Administration , Global Head Of Development For The Healthcare , European Medicines Agency , Committee For Medicinal Products Human Use , Medicinal Products , Human Use , Danny Bar Zohar , Global Head , New England Journal , Lung Cancer , Merck Press Releases , Media Contact , Ral Met Inhibitor , Etex14 Skipping , Committee For Medicinal Products , European Medicines Agency , Non Small Cell Lung Cancer , Esenchymal Epithelial Transition , European Commission , Danny Bar Zohar , Ral Monotherapy Treatment , Transformative Medicines , Dna Damage Response ,